3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Prostatic Neoplasms
3
Brain Neoplasms
2
Urinary Bladder Neoplasms
1
Solid Tumor
1
Ovarian Neoplasms
1
Oligodendroglioma
1
Neoplasms
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Lymphoma, T-Cell, Cutaneous
1
Lung Neoplasms
1
Head and Neck Neoplasms
1
Glioma
1
Glioblastoma
1
Breast Neoplasms
1
Astrocytoma
1
Advanced Solid Tumor
1
Adenocarcinoma of Lung
1
Interventions
pembrolizumab
11
Injections
10
tislelizumab
7
Nivolumab
4
Irinotecan
4
Cetuximab
4
cediranib
3
Paclitaxel
3
PM 01183
3
Leucovorin
3
Gemcitabine
3
Fluorouracil
3
Cisplatin
3
toripalimab
2
spartalizumab
2
serabelisib
2
olaparib
2
glumetinib
2
camrelizumab
2
apatinib
2
adagrasib
2
Therapeutics
2
Pemetrexed
2
Oxaliplatin
2
Midazolam
2
Drug Therapy
2
Docetaxel
2
Digoxin
2
Cyclophosphamide
2
Carboplatin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Advanced Solid Tumor
×
BID protein, human
×
Clear all
NCT06560632
2026-01-16
POLAR
Repare Therapeutics
Phase 1
Terminated
26 enrolled
14 charts